Injectable paromomycin for Visceral leishmaniasis in India.

Abstract

BACKGROUND:

Visceral leishmaniasis (kala-azar) affects large, rural, resource-poor populations in South Asia, Africa, and Brazil. Safe, effective, and affordable new therapies are needed. We conducted a randomized, controlled, phase 3 open-label study comparing paromomycin, an aminoglycoside, with amphotericin B, the present standard of care in Bihar, India.

METHODS:

In four treatment centers for visceral leishmaniasis, 667 patients between 5 and 55 years of age who were negative for the human immunodeficiency virus and had parasitologically confirmed visceral leishmaniasis were randomly assigned in a 3:1 ratio to receive paromomycin (502 patients) at a dose of 11 mg per kilogram of body weight intramuscularly daily for 21 days or amphotericin B (165 patients) at a dose of 1 mg per kilogram intravenously every other day for 30 days. Final cure was assessed 6 months after the end of treatment; safety assessments included daily clinical evaluations and weekly laboratory and audiometric evaluations. Noninferiority testing was used to compare 6-month cure rates, with a chosen margin of noninferiority of 10 percentage points.

RESULTS:

Paromomycin was shown to be noninferior to amphotericin B (final cure rate, 94.6% vs. 98.8%; difference, 4.2 percentage points; upper bound of the 97.5% confidence interval, 6.9; P<0.001). Mortality rates in the two groups were less than 1%. Adverse events, which were more common among patients receiving paromomycin than among those receiving amphotericin B (6% vs. 2%, P=0.02), included transient elevation of aspartate aminotransferase levels (>3 times the upper limit of the normal range); transient reversible ototoxicity (2% vs. 0, P=0.20); and injection-site pain (55% vs. 0, P<0.001); and in patients receiving amphotericin B, as compared with those receiving paromomycin, nephrotoxicity (4% vs. 0, P<0.001), fevers (57% vs. 3%), rigors (24% vs. 0, P<0.001), and vomiting (10% vs. <1%, P<0.001).

CONCLUSIONS:

Paromomycin was shown to be noninferior to amphotericin B for the treatment of visceral leishmaniasis in India. (ClinicalTrials.gov number, NCT00216346.)

• Authors: Shyam Sundar, T K Jha, Chandreshwar P Thakur, Prabhat K Sinha, Sujit K Bhattacharya
• Journal: The New England journal of medicine (N Engl J Med) Vol. 356 Issue 25 Pg. 2571-81 (Jun 21 2007) ISSN: 1533-4406 [Electronic] United States
• PMID: 17582067 (Publication Type: Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright 2007 Massachusetts Medical Society.

Chemical References

• Antiprotozoal Agents
• Paromomycin
• Amphotericin B

Topics

• Adolescent
• Adult
• Amphotericin B (adverse effects, therapeutic use)
• Animals
• Antiprotozoal Agents (administration & dosage, adverse effects, therapeutic use)
• Audiometry
• Child
• Child, Preschool
• Disease Reservoirs
• Female
• Hearing Disorders (chemically induced, diagnosis)
• Humans
• India
• Infusions, Intravenous
• Injections, Intramuscular
• Kidney Diseases (chemically induced)
• Leishmania donovani
• Leishmaniasis, Visceral (drug therapy, mortality)
• Male
• Middle Aged
• Paromomycin (administration & dosage, adverse effects, therapeutic use)
• Prospective Studies
• Treatment Outcome